Reading ALEC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALEC free→Reading ALEC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALEC free→QuarterlyIQ Insights · ALEC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. On May 7, 2026, Alector, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Sales Agreement ”) with TD Securities (USA) LLC (“ TD Cowen ”), pursuant to which the Company may offer and sell from time to time through TD Cowen up to $125,000,000 of shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), in such share amounts as the Company may specify by notice to TD Cowen, in accordance with…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2025, the board of directors of Alector, Inc. (“Alector”) appointed Neil Berkley as Alector’s Chief Financial Officer. Mr. Berkley had been serving as Interim Chief Financial Officer of Alector since June 2025. Mr. Berkley will continue serving as Chief Business Officer and as the principal financial officer of Alector. There are no…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 20, 2025, Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of the Company, informed the Company of her resignation from her position effective December 22, 2025, to pursue other professional opportunities. Dr. Kenkare-Mitra’s resignation is not the result of any disagreement with the Company related to its operat…
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly stated by specific reference in such filing.
Costs Associated with Exit or Disposal Activities. On October 21, 2025, the Company committed to a plan to reduce its workforce (the “Plan”) by approximately 49% in order to align resources with the Company’s strategic priorities. Based upon the results of the Company’s Phase 3 INFRONT-3 clinical trial evaluating the safety and efficacy of latozinemab (AL001) in individuals with frontotemporal dementia due to a GRN mutation (FTD- GRN ), the Company is discontinuing the open-label extension po…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2025, Dr. Marc Grasso gave notice of his decision to resign from his position as Chief Financial Officer of Alector, Inc. (“Alector”) in order to pursue other opportunities. His resignation will be effective on June 20, 2025. Dr. Grasso has served as Alector’s Chief Financial Officer since February 2022, and Alector extends its gratitude…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2025, Dr. Gary Romano gave notice of his decision to resign from his position as Chief Medical Officer of Alector, Inc. (the “Company”) in order to pursue other opportunities. His resignation will be effective on April 25, 2025. Dr. Romano has served as the Company’s Chief Medical Officer since May 2022, and the Company extends its gra…
Costs Associated with Exit or Disposal Activities. On March 7, 2025, Alector, Inc. (“Alector” or “the Company”) committed to a plan to reduce its workforce (the “Plan”) by approximately 13% as part of its cost reduction initiatives in order to align resources with the Company’s strategic priorities, including advancing its preclinical and research pipeline. The Company initiated a reduction in force impacting approximately 25 employees across the organization. The Company continues to expect…
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.